New developments in cancer pain therapy.
This review will summarize some of the potentially useful new drugs and therapies, which have already been applied in clinical practice or will potentially become available for cancer pain management in the near future. Included will be an introduction to drugs, which effectively relieve the breakthrough pain, a group of new sustained release long-acting opioids, Cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drug (NSAIDs), alpha-2 agonists, ion channel blockers, N-methyl-D-aspartate (NMDA) receptor antagonists, and new delivery systems.
Chiang
J S
JS
Department of Anesthesiology, University of Texas, M.D. Anderson Cancer Center, Houston, USA.
D000313:Adrenal Medulla / Q000166:cytology; D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000701:Analgesics, Opioid / Q000627:therapeutic use; D017690:Cell Transplantation; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D005283:Fentanyl / Q000008:administration & dosage; D006801:Humans; D010146:Pain / Q000503:physiopathology*; D010148:Intractable Pain / Q000628:therapy*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D020960:omega-Conotoxins / Q000627:therapeutic use
D000316:Adrenergic alpha-Agonists; D000701:Analgesics, Opioid; D016861:Cyclooxygenase Inhibitors; D016194:Receptors, N-Methyl-D-Aspartate; D020960:omega-Conotoxins; C078452:ziconotide; D005283:Fentanyl